The strong beat and raised guidance signal accelerating bioprocessing demand and market share gains. The BioLife acquisition adds a high-margin, recurring-revenue cell therapy platform. Watch for integration updates and margin trajectory in coming quarters; the stock may re-rate higher if organic momentum continues.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 28 $145.34entry
- T+1 · 4mo ago −2.83%α −1.29% · $141.23
- T+5 · 3mo ago +1.18%α −1.09% · $147.06
- T+20 · 3mo ago +25.01%α +21.63% · $181.69
- T+60 · 26d ago +23.85%α +19.50% · $180.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company raised full-year 2026 guidance for organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, while also announcing a definitive agreement to acquire BioLife Solutions, a strategic move into cell therapy consumables.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $204M, +12% reported and +13% organic YoY
- Adjusted EPS $0.54 vs consensus $0.45 (beat by 20.4%)
- GAAP EPS $0.09 vs $0.26 YoY due to acquisition/amortization costs
- Raised FY26 guidance: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09
- Announced definitive agreement to acquire BioLife Solutions (cell therapy consumables)
- Adjusted operating margin expanded to 16.7% from 12.0% YoY
- Cash and marketable securities $810M at June 30, 2026
Financial Impact
Revenue growth of 12% YoY and adjusted EPS growth of 46% YoY; full-year guidance raised by ~$0.10 at midpoint
Risk Factors
- Integration risk from BioLife acquisition; potential dilution from stock issuance
- GAAP EPS depressed by amortization and deal costs may cause confusion
- Macro headwinds in biotech funding could slow customer orders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-318853 |
| Document: 0001193125-26-318853-index.html | 0001193125-26-318853 |
| Document: 0001193125-26-318853.txt | 0001193125-26-318853 |
| 8-K Data (Synthetic) | 0001193125-26-318853 |
Track record
16 reports on RGEN
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.47% at T+60 after the Jul 22, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $178.94 Now $162.78 −9.03% settles Feb 5
- Oct 30, 202617d ago 8-K Neutral 5/10 Entry $176.94 Now $162.78 −8.00% settles Jan 28
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $175.80 Now $162.78 −7.41% settles Jan 25
- Oct 15, 20264w ago Institutional Cluster Mixed 3/10 Entry $184.17 Now $162.78 −11.61% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $167.22 Now $162.78 −2.66% settles Jan 4
- Oct 6, 20265w ago 8-K Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
- Aug 24, 202611w ago S-4 Neutral 6/10 Entry $181.69 Now $162.78 −10.41% settles Nov 18
- Jul 28, 202615w ago 8-K Bullish 7/10 Viewing Entry $145.34 to $180.01 Now $162.78 +12.00% ▲ +23.85% +19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers